LY 4065967
Alternative Names: LY-4065967Latest Information Update: 17 Oct 2024
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 19 Sep 2024 Preclinical trials in Unspecified in USA (PO) prior to September 2024
- 19 Sep 2024 Eli Lilly and Company plans a phase I PK trial for Healthy volunteers in Japan (PO) (NCT06594159)